These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18633194)

  • 1. Sleep-predominant lowering of ambulatory blood pressure by bedtime inhalation of a novel muscarinic M3 receptor antagonist: a new "bronchoantihypertensive" strategy targeting the lung in hypertension with chronic obstructive pulmonary disease.
    Kario K; Uno H; Shimada K
    Hypertens Res; 2008 Apr; 31(4):817-21. PubMed ID: 18633194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium effective in treatment of COPD.
    Kripke C
    Am Fam Physician; 2005 Dec; 72(11):2219-20. PubMed ID: 16345146
    [No Abstract]   [Full Text] [Related]  

  • 3. Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure.
    Kario K
    Hypertens Res; 2009 Jun; 32(6):428-32. PubMed ID: 19494815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors].
    Abad Santos F; Novalbos J; Gallego Sandín S; Gálvez Múgica MA
    An Med Interna; 2003 Apr; 20(4):201-5. PubMed ID: 12768836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.
    Hermida RC; Ayala DE; Chayan L; Mojon A; Fernandez JR
    Chronobiol Int; 2009 Jan; 26(1):61-79. PubMed ID: 19142758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role?
    Trevethick M; Clarke N; Strawbridge M; Yeadon M
    Curr Opin Pharmacol; 2009 Jun; 9(3):250-5. PubMed ID: 19286423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PHARMAC responds on long-acting inhalers for COPD.
    Metcalfe S; Dougherty S
    N Z Med J; 2005 Nov; 118(1225):U1743. PubMed ID: 16286950
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    Gordon E; Lazarus SC
    J Allergy Clin Immunol; 2009 Nov; 124(5):873-80; quiz 881-2. PubMed ID: 19895979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tiotropium: new about known].
    Stepanian IE
    Ter Arkh; 2008; 80(3):82-4. PubMed ID: 18441692
    [No Abstract]   [Full Text] [Related]  

  • 10. M(2)-β(2) interaction: a basis for combined bronchodilator treatment.
    López-Campos JL
    Arch Bronconeumol; 2013 Jul; 49(7):279-81. PubMed ID: 23122560
    [No Abstract]   [Full Text] [Related]  

  • 11. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.
    Gershon AS; Wang L; To T; Luo J; Upshur RE
    COPD; 2008 Aug; 5(4):229-34. PubMed ID: 18671148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obstructive sleep apnea syndrome and hypertension: mechanism of the linkage and 24-h blood pressure control.
    Kario K
    Hypertens Res; 2009 Jul; 32(7):537-41. PubMed ID: 19461649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience of practical use of sustained-release M-cholinolytic agent thiotropium bromide (Spiriva) in patients with chronic obstructive lung disease].
    Shmelev EI; Khmel'kova MA
    Probl Tuberk Bolezn Legk; 2006; (5):53-5. PubMed ID: 16850926
    [No Abstract]   [Full Text] [Related]  

  • 14. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
    Drescher GS; Carnathan BJ; Imus S; Colice GL
    Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should reducing nocturnal blood pressure be a therapeutic target in CKD? The time is ripe for a clinical outcomes trial.
    Rahman M; Appel LJ
    Am J Kidney Dis; 2007 Dec; 50(6):901-3. PubMed ID: 18037089
    [No Abstract]   [Full Text] [Related]  

  • 16. On comparing different devices of inhalation products.
    García Arieta A
    Respir Med; 2009 Nov; 103(11):1774-5; author reply 1776. PubMed ID: 19692222
    [No Abstract]   [Full Text] [Related]  

  • 17. [Arterial hypertension in patients with chronic obstructive pulmonary disease in combination with coronary artery disease].
    Klester EB; Shoĭkhet IaN
    Ter Arkh; 2008; 80(9):13-7. PubMed ID: 19555029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
    Glossop PA; Watson CA; Price DA; Bunnage ME; Middleton DS; Wood A; James K; Roberts D; Strang RS; Yeadon M; Perros-Huguet C; Clarke NP; Trevethick MA; Machin I; Stuart EF; Evans SM; Harrison AC; Fairman DA; Agoram B; Burrows JL; Feeder N; Fulton CK; Dillon BR; Entwistle DA; Spence FJ
    J Med Chem; 2011 Oct; 54(19):6888-904. PubMed ID: 21870878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between lung function, hypertension and blood pressure medication.
    Schnabel E; Nowak D; Brasche S; Wichmann HE; Heinrich J
    Respir Med; 2011 May; 105(5):727-33. PubMed ID: 21276721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.